We are very pleased about the recent publication of the clinical study on women with low bone density in Journal of Internal Medicine conducted by Professor Mattias Lorentzon and colleagues at Gothenburg university.
Due to questions received by BioGaia in connection to media coverage of the study BioGaia would like to clarify the following:
- The product used in the recently published study from Gothenburg university is a study product and is not available for sale to end consumer. BioGaia is working on developing a commercial product with Lactobacillus reuteri ATCC PTA 6475.
- The women who participated in the study had low bone density, not osteoporosis. The results showed that the loss in bone density was halved in the group receiving active substance compared to placebo. It is the first time that these positive results have been shown in humans. Further studies are planned and BioGaia hopes that they will confirm these promising results.
- The bacterial strain Lactobacillus reuteri ATCC PTA 6475 is available in BioGaia’s product BioGaia Gastrus. However, in a lower dose and in combination with the patented and well-documented probiotic strain Lactobacillus reuteri DSM 17938. BioGaia Gastrus has not been used in clinical trials on women with low bone density or osteoporosis.
Kristina Magnusson Borg, Vice President Discovery and Research, BioGaia